Non-small cell lung cancer
Conditions
Sponsors
The First Affiliated Hospital of Chongqing Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Age range of 18 to 75 years old (calculated from the day of signing informed consent); 2. Patients diagnosed with non-small cell lung cancer through imaging or pathological examination; 3. Disease progression after at least two systemic treatments; 4. According to the criteria for evaluating the efficacy of solid tumors (RECIST version 1.1), at least one lesion that has not received radiation therapy, has not received other local therapies, and can obtain tumor tissue (which can be a single lesion source or multiple lesions combined) is used for organoid establishment; 5. ECOG physical fitness status score 0-1 points; 6. Expected survival time>3 months; 7. Before tumor sampling, there must be imaging records of disease progression after the last treatment; 8. The patient provides informed consent and signs a written consent form; 9. The patient has good compliance and voluntarily accepts follow-up, treatment, laboratory tests, and other research steps according to the plan.
Exclusion criteria
Exclusion criteria: 1. Individuals with extremely weakened overall condition who cannot tolerate bronchoscopy or lung biopsy; 2. Individuals with acute suppurative inflammation of the respiratory tract accompanied by high fever, acute asthma attacks, and ongoing hemoptysis; 3. Have a history of interstitial lung disease, non infectious pneumonia or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc; 4. The patient has active leptomeningeal disease or brain metastasis; 5. Diagnosed with malignant diseases other than NSCLC within 5 years prior to the first administration (excluding curative basal cell carcinoma, squamous cell carcinoma, and/or excised carcinoma in situ); 6. History of immunodeficiency, including positive HIV serum test; 7. Active hepatitis B without treatment (defined as HBsAg positive and HBV-DNA copy number detected is greater than the upper limit of normal value in the laboratory of the research center); 8. Existence of any serious or uncontrollable systemic disease; 9. Pregnant or lactating female patients; 10. The researchers believe that patients who are not suitable to participate in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression free survival;Overall survival;Organoid establishment rate;Accuracy of organoid-based drug sensitivity testing; | — |
Countries
China
Contacts
Public ContactJiang Shan
The First Affiliated Hospital of Chongqing Medical University
Outcome results
None listed